Company Announcement Date: April 20, 2020
FDA Publish Date: April 20, 2020
Product Type: Drugs Reason for Announcement: Presence of Particulate Matter Company Name: Fresenius Kabi USA, LLC
Brand Name: Fresenius Kabi Product Description: Ketorolac Tromethamine Injection, USP, 30 mg/mL, and Ketorolac Tromethamine Injection, USP, 60 mg/2 mL